IS8406A - 5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni - Google Patents

5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni

Info

Publication number
IS8406A
IS8406A IS8406A IS8406A IS8406A IS 8406 A IS8406 A IS 8406A IS 8406 A IS8406 A IS 8406A IS 8406 A IS8406 A IS 8406A IS 8406 A IS8406 A IS 8406A
Authority
IS
Iceland
Prior art keywords
diaminopyrazolo
pde
pyrimidine
inhibitory activity
inhibitory
Prior art date
Application number
IS8406A
Other languages
English (en)
Inventor
Simon Bell Andrew
Graham Brown David
Neil Dack Kevin
Nathan Abraham Fox David
Roger Marsh Ian
Ian Morrell Andrew
John Palmer Michael
Ann Winslow Carol
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS8406A publication Critical patent/IS8406A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8406A 2003-11-24 2006-04-10 5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni IS8406A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327319.0A GB0327319D0 (en) 2003-11-24 2003-11-24 Novel pharmaceuticals
PCT/IB2004/003747 WO2005049616A1 (en) 2003-11-24 2004-11-12 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY

Publications (1)

Publication Number Publication Date
IS8406A true IS8406A (is) 2006-04-10

Family

ID=29764364

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8406A IS8406A (is) 2003-11-24 2006-04-10 5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni

Country Status (43)

Country Link
EP (1) EP1689751B1 (is)
JP (1) JP4056015B2 (is)
KR (2) KR100893999B1 (is)
CN (4) CN1882591B (is)
AP (1) AP2227A (is)
AR (1) AR046711A1 (is)
AT (1) ATE485297T1 (is)
AU (1) AU2004290643B2 (is)
BR (1) BRPI0416869A (is)
CA (1) CA2546987C (is)
CR (1) CR8416A (is)
CY (1) CY1110933T1 (is)
DE (1) DE602004029705D1 (is)
DK (1) DK1689751T3 (is)
EA (1) EA011772B1 (is)
EC (1) ECSP066580A (is)
ES (1) ES2351622T3 (is)
GB (1) GB0327319D0 (is)
GE (1) GEP20084528B (is)
HR (1) HRP20100651T1 (is)
IL (1) IL175433A (is)
IS (1) IS8406A (is)
MA (1) MA28172A1 (is)
ME (1) ME01216B (is)
MX (1) MXPA06005914A (is)
MY (1) MY140872A (is)
NL (1) NL1027568C2 (is)
NO (1) NO336526B1 (is)
NZ (1) NZ548097A (is)
OA (1) OA13289A (is)
PA (1) PA8617701A1 (is)
PE (1) PE20051061A1 (is)
PL (1) PL1689751T3 (is)
PT (1) PT1689751E (is)
RS (1) RS51556B (is)
SG (1) SG133614A1 (is)
SI (1) SI1689751T1 (is)
TN (1) TNSN06154A1 (is)
TW (1) TWI265031B (is)
UA (1) UA81994C2 (is)
UY (1) UY28625A1 (is)
WO (1) WO2005049616A1 (is)
ZA (1) ZA200602899B (is)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513515A (ja) 2004-09-20 2008-05-01 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006046135A2 (en) * 2004-10-28 2006-05-04 Pharmacia & Upjohn Company Llc Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
MX2007013215A (es) * 2005-05-12 2007-12-12 Pfizer Formas cristalinas anhidras de la n-[1-(2-etoxietil)-5-(n-etil-n- metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo[4,3-d] pirimidina -3-carbonil] metanosulfonamida.
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NL1029244C2 (nl) * 2005-06-10 2006-12-12 Ronald Silfried Marlin Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) * 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
JP6110937B2 (ja) 2012-05-04 2017-04-05 ファイザー・インク ＡＰＰ、ＢＡＣＥ１、およびＢＡＣＥ２の阻害剤としての複素環式置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014045162A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
JP2016502978A (ja) 2012-12-11 2016-02-01 ファイザー・インク ＢＡＣＥ１の阻害剤としてのヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014128585A1 (en) 2013-02-19 2014-08-28 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
EP3052495B1 (en) 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
CA2934391A1 (en) * 2013-12-20 2015-06-25 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
MD20160102A2 (ro) 2014-04-01 2017-04-30 Pfizer Inc. Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei
CN109999039A (zh) * 2014-04-04 2019-07-12 H.隆德贝克有限公司 作为pde1抑制剂的卤化的喹唑啉-thf-胺
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
JP6506833B2 (ja) 2014-08-06 2019-04-24 ファイザー・インク イミダゾピリダジン化合物
MX368162B (es) * 2014-12-08 2019-09-20 Janssen Sciences Ireland Uc Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr).
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
PT3310784T (pt) 2015-06-17 2020-11-30 Pfizer Compostos tricíclicos e a sua utilização como inibidores de fosfodiesterase
EP3353183A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3]thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl]amides
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
EP3419979B1 (en) 2016-02-23 2020-01-29 Pfizer Inc 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
WO2018002760A1 (en) 2016-07-01 2018-01-04 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
JP7263266B2 (ja) 2017-06-22 2023-04-24 ファイザー・インク ジヒドロ－ピロロ－ピリジン誘導体
FI3768669T3 (fi) 2018-03-23 2023-04-26 Pfizer Piperatsiiniatsaspirojohdannaisia
CN118834214A (zh) 2018-06-04 2024-10-25 爱克思科技有限公司 作为腺苷受体拮抗剂的吡唑并嘧啶化合物
TWI837169B (zh) * 2018-08-24 2024-04-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021154668A1 (en) * 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2023171556A1 (ja) * 2022-03-10 2023-09-14 積水化学工業株式会社 ウイルス感染阻止剤、ウイルス感染阻止製品、ウイルス感染阻止塗料及び樹脂組成物
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
GB9823102D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
JP2002528456A (ja) * 1998-10-23 2002-09-03 ファイザー・インク 性的機能障害の処置のためのピラゾロピリミジノン系ｃＧＭＰ阻害薬
DE10031236A1 (de) * 2000-06-27 2002-01-10 Qiagen Gmbh Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DK1348707T3 (da) * 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
WO2004096810A1 (en) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Also Published As

Publication number Publication date
CN101362765A (zh) 2009-02-11
EA200600677A1 (ru) 2006-12-29
DK1689751T3 (da) 2011-01-17
HRP20100651T1 (hr) 2011-01-31
GB0327319D0 (en) 2003-12-24
TNSN06154A1 (fr) 2007-11-15
EP1689751B1 (en) 2010-10-20
CN1882591B (zh) 2011-08-10
NL1027568C2 (nl) 2005-11-30
CN101362765B (zh) 2011-02-02
NZ548097A (en) 2008-12-24
KR20080052666A (ko) 2008-06-11
MXPA06005914A (es) 2006-06-27
CN101362764B (zh) 2011-04-20
KR20070026334A (ko) 2007-03-08
BRPI0416869A (pt) 2007-03-27
UA81994C2 (en) 2008-02-25
UY28625A1 (es) 2005-06-30
CN101362764A (zh) 2009-02-11
HK1099286A1 (en) 2007-08-10
KR100848216B1 (ko) 2008-07-24
ME01216B (me) 2013-03-20
SI1689751T1 (sl) 2011-01-31
MY140872A (en) 2010-01-29
GEP20084528B (en) 2008-11-10
KR100893999B1 (ko) 2009-04-20
CA2546987C (en) 2009-05-12
TW200520758A (en) 2005-07-01
CN1882591A (zh) 2006-12-20
NL1027568A1 (nl) 2005-05-26
RS51556B (en) 2011-06-30
AP2227A (en) 2011-03-29
PE20051061A1 (es) 2005-12-12
WO2005049616A1 (en) 2005-06-02
PL1689751T3 (pl) 2011-03-31
IL175433A0 (en) 2006-09-05
NO20062950L (no) 2006-08-23
EP1689751A1 (en) 2006-08-16
JP2007512314A (ja) 2007-05-17
AR046711A1 (es) 2005-12-21
CA2546987A1 (en) 2005-06-02
CY1110933T1 (el) 2015-06-10
AP2006003591A0 (en) 2006-04-30
ES2351622T3 (es) 2011-02-08
PA8617701A1 (es) 2005-08-04
CN101647802A (zh) 2010-02-17
JP4056015B2 (ja) 2008-03-05
TWI265031B (en) 2006-11-01
OA13289A (en) 2007-01-31
PT1689751E (pt) 2010-11-29
EA011772B1 (ru) 2009-06-30
SG133614A1 (en) 2007-07-30
ZA200602899B (en) 2007-07-25
MA28172A1 (fr) 2006-09-01
IL175433A (en) 2011-08-31
NO336526B1 (no) 2015-09-21
AU2004290643B2 (en) 2008-08-07
ECSP066580A (es) 2006-12-20
HK1128917A1 (en) 2009-11-13
CR8416A (es) 2006-11-15
ATE485297T1 (de) 2010-11-15
WO2005049616A8 (en) 2006-06-01
DE602004029705D1 (de) 2010-12-02
AU2004290643A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
IS8406A (is) 5,7-díamínópýrasóló [4,3-d] pýrimidín með PDE-5 hindrandi virkni
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
DK1797099T3 (da) Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
ATE384725T1 (de) Pyrimido 4,5-d pyrimidinderivate mitantikrebswirkung
NO2017014I1 (no) 6-acetyl-8-cyclopentyl-5-metyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-on
NO20040540L (no) 4-amino-6-fenylpyrrolo[2,3-D]pyrimidinderivater.
ATE529412T1 (de) Herbizide pyrimidine
DK1487805T3 (da) Pyrimidinderivater
AP2005003403A0 (en) Substituted pyrimidinones.
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ATE326467T1 (de) Imidazo 1,2-aöpyridine
AP2157A (en) 2-substituted pyrimidines.
DE50103649D1 (de) 2-aminoalkyl-thieno[2,3-d]pyrimidine
AP2006003496A0 (en) 2-Substituted pyrimidines.
IL173347A0 (en) 7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
TJ431B (en) 2-Brom-7-methil-5-oxo-5h-1,3,4-thyodyazol-(3,2-a)pyrimidin, has antibacterial activity
GB0301985D0 (en) Passive battlefield I.F.F. system
ES1050939Y (es) Celosia antivandalica.
ES1051950Y (es) Celosia fija.